Know Cancer

forgot password

A Pilot Study of Four-Dimensional Conformal Image Guided Accelerated Partial Breast Irradiation In The Treatment Of Stage 0 and l Breast Cancer

50 Years
Open (Enrolling)
Breast Cancer

Thank you

Trial Information

A Pilot Study of Four-Dimensional Conformal Image Guided Accelerated Partial Breast Irradiation In The Treatment Of Stage 0 and l Breast Cancer

This is a pilot study enrolling about 30 patients to evaluate the feasibility of using 4D CT
and daily image guidance in Accelerated Partial Breast Irradiation (APBI) to decrease set-up
error and individualized planning target volumes to limit the non-target breast tissue dose.
The two specific breasts constraints which shall be decreased are the V50 (percent volume of
breast receiving 50% of the prescribed dose) and the V100 (percent volume of breast
receiving 100% of the prescribed dose). The goal will be to decrease these to 45% and 23.5%
respectively, which is down 33% from the NSABP B39 standard of 60% and 35%.

Inclusion Criteria:

- The patient must consent to be in the study and must have a signed an approved
consent form conforming with institutional guidelines.

- Patient must be > 50 years old.

- The patient should have a life expectancy of at least two years with a karnofsky
performance status > 70.

- The patient must have stage 0 or I breast cancer.

- On histological examination, the tumor must be DCIS or invasive adenocarcinoma of the

- Surgical treatment of the breast must have been lumpectomy. The margins of the
resected specimen must be histologically free of tumor (>2mm, DCIS and invasive).
Re-excision of surgical margins is permitted.

- Gross disease must be unifocal with pathologic (invasive and/or DCIS) tumor size 2 cm
or less. (Patients with microscopic multifocality are eligible as long as total
pathologic tumor size is 2 cm or less.)

- Patients with invasive breast cancer are required to have axillary staging which can
include sentinel node biopsy alone (if negative), sentinel node biopsy followed by
axillary dissection or sampling with a minimum total of 6 axillary nodes or axillary
dissection alone (with a minimum of 6 axillary nodes). Axillary staging is NOT
required for patients with DCIS.

- The patient must have simulation within 8 weeks/56 days of the final surgery for
their breast cancer (lumpectomy, re-excision of margins, or axillary staging

- Patients with a history of non-ipsilateral breast malignancies are eligible if they
have been disease-free for 2 or more years prior to enrollment. Patients with the
following cancers are eligible even if diagnosed and treated within the past 2 years:
carcinoma in situ of the cervix, colon, melanoma in situ, and basal cell and squamous
cell carcinoma of the skin.

- Chemotherapy is permitted if planned for ≥ 2 weeks after radiation.

- Urine pregnancy test must be performed and be negative on all women younger than 60
who have not had a tubal ligation, oophorectomy, or hysterectomy.

- Separate incisions for the lumpectomy and sentinel node biopsy should be present. Use
of only one incision will typically result in a contiguous cavity with the tumor bed
and the sentinel node sampling, and inability of the radiation oncologist to
delineate the tumor bed from the sentinel node bed.

- The patient must have a cavity which is able to be targeted with external beam APBI,
either through surgical clip placement, or CVS 3 or higher. The cavity to whole
breast ratio must be 30% or less.

Exclusion Criteria:

- Men are not eligible for this study as men are not breast conservation candidates.

- T0, T2 (> 2.0 cm), T3, node positive, stage III or IV breast cancer.

- Any positive axillary nodes.

- Palpable or radiographically suspicious ipsilateral or contralateral axillary,
supraclavicular, infraclavicular or internal mammary nodes, unless biopsy proven to
be negative for tumor.

- Suspicious microcalcifications, densities or palpable abnormalities in either breast
unless biopsy proven to be benign.

- Non-epithelial breast malignancies such as sarcoma or lymphoma.

- Proven multicentric carcinoma in more than one quadrant or separated by more than 2

- Paget's disease of the nipple.

- History of invasive breast cancer or DCIS in the same breast.

- Surgical margins that cannot be microscopically assessed or are less then 2 mm.

- Collagen vascular disease, specifically dermatomyositis with a CPK level above normal
or with an active skin rash, systemic lupus erythematosis or scleroderma.

- Pregnancy or lactation at the time of proposed radiation. Women of reproductive
potential must agree to use an effective non-hormonal method of contraception during

- Psychiatric or addictive disorders or other conditions that, in the opinion of the
treating physician, would preclude the patient from meeting the study requirements.

- Patients with coexisting medical conditions in whom life expectancy is < 2 years.

- Patients with skin involvement, regardless of tumor size.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Reduction in incidental radiation

Outcome Description:

Reduction in breast radiation V50 less than 45% and V100 less than 23.5%.List instrument or scale

Outcome Time Frame:

5 day

Safety Issue:


Principal Investigator

Suzanne Evans, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Yale University


United States: Institutional Review Board

Study ID:




Start Date:

February 2012

Completion Date:

January 2018

Related Keywords:

  • Breast Cancer
  • Breast Cancer
  • Radiation for Breast Cancer
  • Breast Neoplasms



Yale New Haven HospitalNew Haven, Connecticut  06520